Trial Profile
An Open-Label, Phase 2 Study of the Farnesyl Transferase Inhibitor ZARNESTRA (R115777) as Post-Consolidation Therapy for Acute Myeloid Leukemia (AML) in Patients Age 60 Years and Older
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 May 2010
Price :
$35
*
At a glance
- Drugs Tipifarnib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 04 May 2010 Actual patient number (88) added as reported by ClinicalTrials.gov.
- 04 May 2010 Actual patient number (88) added as reported by ClinicalTrials.gov.
- 04 May 2010 Actual patient number (88) added as reported by ClinicalTrials.gov.